- $1.53bn
- $1.53bn
- $2.07m
Brief: Cyclerion Announces Transformational Relaunch As A Neuropsychiatric Company
Brief: Cyclerion Therapeutics Inc Files For Mixed Shelf Of Up To $25 Million
U.S. STOCKS ON THE MOVE-Korro Bio, Arrowhead Pharma, Structure Therapeutics
Cyclerion Therapeutics falls as CEO steps down
Brief: Cyclerion Therapeutics Names Regina Graul As President
Brief: Cyclerion Therapeutics To Increase Size Of Board Of Directors To Six Directors
Brief: Cyclerion Therapeutics Co And Anjeza Gjino, Co's CFO, Entered Into A Separation And Release Of Claims Agreement
Brief: Cyclerion Therapeutics Says Tisento Launches With $81 Mln From Top-Tier Investor Syndicate, Promising Cyclerion Assets
Brief: Cyclerion Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Cyclerion Announces Reverse Stock Split
U.S. STOCKS ON THE MOVE-Energy firms, crypto stocks, Walt Disney
U.S. STOCKS ON THE MOVE-Cyclerion, banks, Jounce Therapeutics
Cyclerion jumps on FDA's 'orphan drug' tag for nervous system disease drug
Brief: Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation For Zagociguat
Brief: Cyclerion Concludes Unsolicited Proposal Is Not In The Best Interest Of The Company
Cyclerion changes focus of drugs, announces job cuts; shares tumble
Brief: Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
Brief: Cyclerion Announces CY6463 Clinical Pipeline Progress, Q2 Results
Brief: Cyclerion Reports Positive Topline Clinical Data For CY6463